Overview: Methotrexate TestIntroduction: The Methotrexate Test measures methotrexate levels to monitor cancer treatment, preventing toxicity. Following 2023 NCCN guidelines, it uses toxicology methods for high specificity, supporting drug monitoring. This test is critical for guiding treatment adjustments, preventing toxicity, and improving outcomes in oncology for patients receiving methotrexate for cancers like leukemia or lymphoma.
Other Names: Methotrexate Assay, MTX Level Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Methotrexate monitoring began in the 1970s with chemotherapy research. Analytical methods improved in the 2000s, enhancing detection sensitivity.
Purpose: Measures methotrexate levels to monitor cancer treatment, guides dosage adjustments, and prevents toxicity.
Test Parameters: 1. Methotrexate Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of chemotherapy, renal function, or toxicity symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document chemotherapy history, renal dysfunction, or symptoms like nausea or mucositis. Include current medications, especially folinic acid.
Consent: Written consent required, detailing the tests purpose, methotrexate toxicity implications, and risks of blood collection.
Procedural Considerations: Uses toxicology methods (e.g., high-performance liquid chromatography) to measure methotrexate levels in serum or plasma. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for chemotherapy monitoring.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Renal impairment may alter drug clearance.
Clinical Significance: Elevated methotrexate levels indicate risk of toxicity, guiding leucovorin rescue or dose adjustment. Normal levels support continued therapy.
Specialist Consultation: Consult an oncologist or pharmacologist for result interpretation and treatment planning.
Additional Supporting Tests: Renal function tests, liver function tests, or CBC to monitor methotrexate therapy.
Test Limitations: Levels vary with dosing schedule; clinical correlation is needed. Sample timing affects accuracy.
References: NCCN Chemotherapy Guidelines, 2023; Journal of Clinical Oncology, Widemann BC, 2022.
